FDA issues guidance on remote interactive inspections: The FDA has issued draft guidance explaining how it plans to request and conduct voluntary remote interactive evaluations of drug manufacturing sites and other facilities covered by its bioresearch monitoring program. “When facilities agree to participate in a remote interactive evaluation, FDA expects them to cooperate with the same level of transparency as they would during an FDA inspection,” the FDA wrote, adding that it expects staff “to be available at scheduled times for interviews and other virtual interactions, and we expect the facility to be operational to the extent possible for FDA to evaluate areas and operations of interest.”